These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9237703)

  • 1. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
    Berman PW; Gray AM; Wrin T; Vennari JC; Eastman DJ; Nakamura GR; Francis DP; Gorse G; Schwartz DH
    J Infect Dis; 1997 Aug; 176(2):384-97. PubMed ID: 9237703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
    Connor RI; Korber BT; Graham BS; Hahn BH; Ho DD; Walker BD; Neumann AU; Vermund SH; Mestecky J; Jackson S; Fenamore E; Cao Y; Gao F; Kalams S; Kunstman KJ; McDonald D; McWilliams N; Trkola A; Moore JP; Wolinsky SM
    J Virol; 1998 Feb; 72(2):1552-76. PubMed ID: 9445059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization.
    Migasena S; Suntharasamai P; Pitisuttithum P; Kitayaporn D; Wasi C; Huang W; Vanichseni S; Koompong C; Kaewkungwal J; Raktham S; Ippolito T; Hanson C; Gregory T; Heyward WL; Berman P; Francis D
    AIDS Res Hum Retroviruses; 2000 May; 16(7):655-63. PubMed ID: 10791876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.
    Kahn JO; Steimer KS; Baenziger J; Duliege AM; Feinberg M; Elbeik T; Chesney M; Murcar N; Chernoff D; Sinangil F
    J Infect Dis; 1995 May; 171(5):1343-7. PubMed ID: 7751714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Newman FK; Belshe RB; Berman PW; Gregory TJ; Matthews TJ
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):378-86. PubMed ID: 8807200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.
    Beddows S; Lister S; Cheingsong R; Bruck C; Weber J
    J Virol; 1999 Feb; 73(2):1740-5. PubMed ID: 9882391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine.
    Chujoh Y; Matsuo K; Yoshizaki H; Nakasatomi T; Someya K; Okamoto Y; Naganawa S; Haga S; Yoshikura H; Yamazaki A; Yamazaki S; Honda M
    Vaccine; 2001 Dec; 20(5-6):797-804. PubMed ID: 11738743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
    Zaghouani H; Anderson SA; Sperber KE; Daian C; Kennedy RC; Mayer L; Bona CA
    Proc Natl Acad Sci U S A; 1995 Jan; 92(2):631-5. PubMed ID: 7831341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
    Zolla-Pazner S; Cohen S; Pinter A; Krachmarov C; Wrin T; Wang S; Lu S
    Virology; 2009 Sep; 392(1):82-93. PubMed ID: 19632700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
    Smith AD; Geisler SC; Chen AA; Resnick DA; Roy BM; Lewi PJ; Arnold E; Arnold GF
    J Virol; 1998 Jan; 72(1):651-9. PubMed ID: 9420270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.
    Berman PW; Matthews TJ; Riddle L; Champe M; Hobbs MR; Nakamura GR; Mercer J; Eastman DJ; Lucas C; Langlois AJ
    J Virol; 1992 Jul; 66(7):4464-9. PubMed ID: 1602554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies from HIV-positive and AIDS patients bind to an HIV envelope multivalent vaccine.
    Carlos MP; Yamamura Y; Díaz-Mitoma F; Torres JV
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):317-24. PubMed ID: 10634192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.